Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Recruiting

Phase 1

Phase 2

IMC-F106C & Checkpoint InhibitorsSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Sponsor:

Immunocore Ltd

Code:

NCT04262466

Conditions

Select Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Brenetafusp

Brenetafusp and pembrolizumab

Brenetafusp and chemotherapy

Brenetafusp and monoclonal antibodies and chemotherapy

Brenetafusp and tebentafusp

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-24. This information was provided to ClinicalTrials.gov by Immunocore Ltd on 2024-10-26.